Core Viewpoint - HCW Biologics Inc. has received an extension from the Nasdaq Hearings Panel to regain compliance with listing rules, allowing the company to continue its operations on the Nasdaq Capital Market [1][2]. Company Overview - HCW Biologics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies aimed at extending healthspan by addressing inflammation-related age diseases [1][3]. - The company’s lead product candidate, HCW9302, is developed using the TOBI™ platform, while another drug discovery technology, the TRBC platform, allows for the creation of various immunotherapeutic compounds [3]. Compliance and Listing Status - The Nasdaq Panel granted the company an extension to demonstrate compliance with the Bid Price Rule by April 25, 2025, and all other continued listing rules by June 15, 2025 [2]. - The extension follows a hearing where the company's compliance plan was evaluated [2]. Product Development and Pipeline - HCW Biologics is developing immunotherapeutics that target chronic inflammation, with applications in oncology and other diseases associated with aging [3]. - The TRBC platform has enabled the creation of over 50 molecules, with ongoing preclinical evaluations for several promising candidates [3].
HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements